

12 March 2023

Use of Biologic Medicines in Gastroenterology

Q1. How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:

- Adalimumab - Humira
- Adalimumab Biosimilar **380 (combined)**
- Etrasimod **0**
- Filgotinib **10**
- Golimumab **10**
- Infliximab - Remicade
- Infliximab Biosimilar **350 (combined)**
- Mirikizumab **0**
- Ozanimod **1**
- Risankizumab **7**
- Tofacitinib **4**
- Upadacitinib **20**
- Ustekinumab **195**
- Vedolizumab **260**

Q2 If you are able to link patient treatment to a disease, could you please provide the number of patients treated in the last 3 months for Ulcerative Colitis ONLY with the following biologic drugs:

- Adalimumab - Humira
- Adalimumab Biosimilar **90 (combined)**
- Etrasimod **0**
- Filgotinib **10**
- Golimumab **10**
- **Infliximab - Remicade**
- Infliximab Biosimilar **130 (combined)**
- Mirikizumab **0**
- Ozanimod **1**
- Risankizumab **0**
- Tofacitinib **4**
- Upadacitinib **6**
- Ustekinumab **30**
- Vedolizumab **140**